TLR13 Activators
TLR13 activators, though not directly engaging with TLR13, significantly influence the receptor's activity by modulating immune responses via various TLRs. Compounds like Pam3CSK4 target TLR1/2, triggering NF-κB signaling pathways that are vital for the upregulation of immune-related genes. This cascade of events could prime TLR13, enhancing its responsiveness to specific ligands by increasing receptor expression or readiness. Conversely, TLR3 and TLR9 agonists, such as Poly(I:C) and CpG Oligodeoxynucleotides, promote type I interferon and cytokine production, which fortifies antiviral defenses and potentially upregulates TLR13, optimizing its response capabilities. Similarly, activation of TLR7/8 by Resiquimod and Imiquimod leads to the release of pro-inflammatory cytokines and type I interferons, fostering an immune environment where TLR13 expression and sensitivity to pathogens is augmented due to the interconnected nature of TLR pathways.
The impact of other TLR agonists, like Lipopolysaccharides (LPS) for TLR4 and Flagellin for TLR5, extends to the MyD88-dependent pathway that many TLRs, including TLR13, share, potentially causing a coordinated increase in innate immune responses and TLR13 activation. Gardiquimod, targeting TLR7, further exemplifies how TLR engagement can amplify immune system reactions and cross-regulate TLR13 activity, thus enhancing pathogen detection and initiating effective immune responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $100.00 $300.00 $500.00 $1528.00 | 12 | |
Resiquimod is an agonist of TLR7/8, which can lead to the activation of NF-κB signaling. The activation of NF-κB can enhance the expression of TLR13 due to the interconnected nature of TLR signaling pathways. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
Imiquimod is another TLR7 agonist that similarly activates the NF-κB pathway, potentially upregulating TLR13 expression as part of a broader TLR response. | ||||||
Polyinosinic acid - polycytidylic acid sodium salt, double-stranded | 42424-50-0 | sc-204854 sc-204854A | 10 mg 100 mg | $139.00 $650.00 | 2 | |
Polyinosinic:polycytidylic acid is a synthetic analog of double-stranded RNA that acts as a TLR3 agonist, initiating antiviral responses that could enhance TLR13 activity indirectly through type I interferon signaling. | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $96.00 $166.00 $459.00 $1615.00 | 12 | |
LPS is a TLR4 ligand that activates the MyD88-dependent signaling pathway, likely enhancing the functional activity of TLR13 as part of the innate immune response. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $154.00 $276.00 $506.00 $1154.00 $19743.00 $32136.00 $69366.00 | 1 | |
Activates TLR7 and could lead to an enhanced TLR13 response by bolstering the antiviral response and subsequent cross-talk between TLR pathways. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
A synthetic triacylated lipopeptide that acts as a TLR1/2 agonist, potentially enhancing TLR13 activity by activating NF-κB signaling. | ||||||